Thursday, March 23Welcome

Aziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key Markets

Ajiyo Biologics

Ajiyo Biologics

Senior team strengthened to advance Aziyo’s commercial and financial goals

SILVER SPRING, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a biological device company with a portfolio of commercial products across four distinct businesses, today announced that Announced major promotions and new hires. It has established itself as a leader in treatment options for patients undergoing implantable medical devices and other surgical procedures.

Courtney Guyer has been promoted to Vice President and General Manager, Women’s Health, said Dr. Sonali Fonseca. She has been appointed Vice President and General Manager of Ortho-Biologics and Emerging Businesses. Jeff Hamet has been promoted to Senior Vice President of Finance and Erica Elchin has been promoted to Vice President of Global Operations.

“Over the past 90 days, my team and I have worked together to organize our company in a way that maximizes shareholder value. We believe we are at an inflection point and these significant additions and promotions will Coupled with your existing team, it provides the leadership bandwidth you need to succeed. It is truly an honor and a pleasure to work with such a dedicated leadership team.”

• Courtney Guyer, Vice President and General Manager, Women’s Health:

Guyer joined Aziyo in 2018 as Vice President of Marketing, bringing global leadership experience with established start-up medical device companies across multiple therapeutic areas. Prior to joining Aziyo, he was Senior Director of Marketing at Medinol, an international cardiovascular company, where he led the pivotal launch of bare-metal and drug-eluting coronary stent products. Previously at LifeCell, he led the marketing team in the US and Globally, working on upstream and downstream launches and product portfolio projects. He has also held sales and marketing roles at Johnson & Johnson and Merck. Guyer received her MBA from the Wharton School of the University of Pennsylvania and a BS in Biology from Penn State University.

• Dr. Sonali Fonseca, Vice President and General Manager of Orthobiologics and Emerging Businesses:

Dr. Fonseca is a proven commercial strategist and leader in biotech and healthcare technology solutions. Prior to that, he served as Vice President of Strategic Initiatives at the Sanford Burnham Prebys Medical Discovery Institute, where he led the translation and commercialization of new medical discoveries. Prior to that, Dr. Fonseca was Commercial Vice President of Operations for Elsevier’s Clinical Paths He franchised Oncology Clinical Decision-Making business. Dr. Fonseca has also worked at PwC Strategy in the US and UK Life Sciences where he focused on M&A and at Deloitte where he advised pharmaceutical and biotech clients on organic growth strategies and execution. Dr. Fonseca completed his Ph.D. He holds a PhD in Pharmacy and Drug Design from the University of Toronto.

• Jeff Hamet, Senior Vice President of Finance:

Hamet joined Aziyo Biologics at its inception and brings over 25 years of senior level finance, accounting and management experience primarily in the life sciences, medical services and high tech industries. He previously served as President and Chief Financial Officer of NeurExpand Brain Center and Vice President and Corporate Controller of Martek Biosciences Corporation. During his tenure at Martech, the company experienced dramatic growth in revenue, profits and employees, leading to his $1.1 billion acquisition by Royal DSM NV. Prior to joining Martek, Hamet was a Finance Director at his IGEN International, Inc. and his ARBROS Communications, Inc. Jeff started his career at his Arthur Andersen LLP, an international accounting firm. I was. He holds a bachelor’s degree in accounting from the University of Maryland and is a certified public accountant.

• Erica Elchin, Vice President of Global Operations:

Elchin is a results-driven biotechnology professional with over 20 years of experience in the biologics, medical device, and pharmaceutical fields. She returns to Aziyo after leading efforts to improve the cell therapy process for the National Bone Marrow Donor Program (NMDP). Previously, she served as Vice President of Technical Services for Aziyo Biologics, where she oversaw quality, regulation, donor services and production technology for the company’s proprietary biologics. In addition, she led her Osiris Therapeutics operations and was responsible for the production of her own portfolio of commercial wound care and orthopedic cell therapy products. Elchin began her career developing virus treatment technologies at Wyeth Vaccines, including the production of FluShield® and her FluMist®. She holds a Master of Science in Environmental Science from Johns Hopkins University and a Bachelor of Science in Biology from Pennsylvania State University.

About Ajiyo Biologics
Aziyo Biologics is a regenerative medicine company with a commercial portfolio of differentiated products focused primarily on improving outcomes for patients undergoing various surgical procedures for implantable medical devices. Since our founding in 2015, we have created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, please visit

Forward-Looking Statements
Any statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Advancing strategic and financial goals, product development, and business potential. Forward-looking statements are defined as “expects,” “believes,” “continues,” “expects,” “targets,” “intends,” “could,” “plans,” “could” ”, “project”, “will”, and other similar words or expressions, or negation of these or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors. This includes, but is not limited to, the risks referenced in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the quarter ended June 30. , 2022, such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (“SEC”). These filings can be accessed on the SEC’s website at and on the investor page. Company website All forward-looking statements speak only as of the date of this press release, except as required by applicable law. , we undertake no obligation to update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise. , change of circumstances or otherwise.

Matt Ferguson
Ajiyo Biologics Co., Ltd.

Courtney Guyer
Ajiyo Biologics Co., Ltd.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *